Table 1. Characteristics of the 131 patients analyzed.
| Characteristics | Patient no. (%) | |
| Gender (M/F) | 42/89 | |
| Median age at transplantation (range) | 8 (1–23) years | |
| Underlying disease | malignant | 98 (75) |
| non-malignant | 33 (25) | |
| Stem cell source | bone marrow | 78 (60) |
| peripheral blood | 42 (32) | |
| cord blood | 11 (8) | |
| Donor type | sibling | 45 (34) |
| unrelated | 57 (44) | |
| haploidentical relative | 29 (22) | |
| Donor/recipient HCMV serostatus | D+/R+ | 51 (39) |
| D−/R+ | 38 (29) | |
| D+/R− | 42 (32) | |
| Conditioning regimen | TBI-based | 61 (47) |
| chemotherapy-based | 70 (53) | |
| GvHD prophylaxis | CS-A | 22 (17) |
| MTX | 1 (1) | |
| CS-A + MTX | 69 (53) | |
| CS-A + steroid | 11 (8) | |
| T-cell depletion | 28 (21) | |
| Administration of ALG | Yes | 86 (66) |
| No | 45 (34) | |
| GvHD | Acute (grade II–IV) | 42 (32) |
| Chronic | 24 (18) | |
| Graft failure, | ||
| -median days (range) after transplantation: | 442 (49–528) | 3 (2) |
| Disease relapse, | ||
| -median days (range) after transplantation: | 247 (35–643) | 35 (36)* |
| Transplantation-related death, | ||
| -median days (range) after transplantation: | 216 (57–869) | 7 (5) |
TBI: total body irradiation; GvHD: graft vs host disease; CS-A: cyclosporine-A; MTX:methotrexate; ALG: anti-lymphocyte globulin methotrexate; ALG: anti-lymphocyte globulin.
*
Among patients with malignant disease.